IMPACT: This trial showed that the addition of fluorouacil to EC-P did not improve survival and increased toxicity. The dose-dense regimen was associated with a significant reduction in the risk of recurrence and death compared with standard-interval chemotherapy. Unlike the CALGB B9741, the benefit was shown for hormone receptor positive and negative subgroups.
Download | Slideshow Summary
Link | Full article (PubMed)